Arvee Laboratories (India) LimitedQ1 FY27 Results & Financial Update
Arvee Laboratories (India) Limited: Q1 FY27 standalone results and company financials – revenue ₹17.41 Cr, PAT ₹1.69 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Arvee Laboratories (India) price & chart
Market price₹189.07
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Arvee Laboratories (India) Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Arvee Laboratories (India) Limited recorded standalone revenue from operations of INR 17.41 crore for the quarter ended 30 June 2026, accompanied by total income of INR 17.41 crore.
Profit before tax (PBT) for the quarter stood at INR 2.29 crore, while profit after tax (PAT) reached INR 1.69 crore, resulting in a net profit margin of approximately 9.73 percent.
Basic and diluted earnings per share (EPS) for the period settled at INR 1.54, reflecting the bottom-line earnings generated across the standalone operating structure during the quarter.
Total expenses for the period absorbed a significant share of top-line inflows, influenced by operational outlays, finance costs of INR 0.06 crore, and depreciation and amortization charges of INR 0.32 crore.
Tax provisioning for the quarter was reported at INR 0.59 crore, factoring into the final PAT calculation derived from pre-tax earnings.
Other income contributed INR 0.18 crore to the financial results, supporting overall earnings alongside core operational revenue streams.
Total income for the quarter stood at INR 17.41 crore, which includes other income of INR 0.18 crore generated during the period.
01 · Business model
What does Arvee Laboratories (India) do?
Arvee Laboratories (India) Limited operates as a specialized chemical manufacturer, producing active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and specialty chemical compounds for diverse medical and industrial applications.
The company's operational model revolves around chemical synthesis and plant-based manufacturing processes, servicing domestic and international pharmaceutical and chemical clients.
Revenue generation relies primarily on the commercial supply of manufactured chemical formulations and intermediaries, reflecting direct exposure to broader pharmaceutical input demand cycles.
02 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹17.41 Cr |
| Total income | ₹17.41 Cr |
| Profit before tax | ₹2.29 Cr |
| Profit after tax | ₹1.69 Cr |
| EPS | ₹1.54 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 9.7% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 13.1% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations reached INR 17.41 crore for Q1 FY27, representing the primary top-line stream for the standalone entity.
Non-operating streams contributed INR 0.18 crore to total income, which stood marginally higher at INR 17.41 crore.
Revenue from operations of INR 17.41 crore was driven by the sale of APIs and pharmaceutical intermediates during the quarter ended 30 June 2026.
Other income added INR 0.18 crore to the total income of INR 17.41 crore for Q1 FY27.
What drove margins
Financing charges for the quarter were recorded at INR 0.06 crore, exerting a minor cost burden on earnings.
Depreciation and amortization expenses totaled INR 0.32 crore, reflecting capital asset utilization during the period.
Tax outlays amounted to INR 0.59 crore against a profit before tax of INR 2.29 crore.
The company achieved a net profit margin of 9.73 percent, with PAT of INR 1.69 crore on total revenue of INR 17.41 crore.
Modest finance costs of INR 0.06 crore and depreciation of INR 0.32 crore supported bottom-line retention during the quarter.
04 · Reported developments
What changed operationally
The company reported a positive standalone net profit of INR 1.69 crore and a PBT of INR 2.29 crore for the quarter.
The company maintained positive profitability with a net profit of INR 1.69 crore and basic EPS of INR 1.54 for Q1 FY27.
05 · Beyond the numbers
What changed beyond the numbers
Reported update
Regulatory Filing
Financial results for the quarter ended 30 June 2026 were filed in compliance with Indian Accounting Standards (Ind AS) via official exchange structured filings.
06 · Key Q&A
The quarter, answered directly
What does Arvee Laboratories (India) do?
Arvee Laboratories (India) Limited operates as a specialized chemical manufacturer, producing active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and specialty chemical compounds for diverse medical and industrial applications.
What is the clearest takeaway from Q1 FY27?
Arvee Laboratories (India) Limited recorded standalone revenue from operations of INR 17.41 crore for the quarter ended 30 June 2026, accompanied by total income of INR 17.41 crore.
What drove revenue or demand?
Revenue from operations reached INR 17.41 crore for Q1 FY27, representing the primary top-line stream for the standalone entity.
What mattered most for margins or profitability?
Financing charges for the quarter were recorded at INR 0.06 crore, exerting a minor cost burden on earnings.
What changed operationally beyond the headline numbers?
Financial results for the quarter ended 30 June 2026 were filed in compliance with Indian Accounting Standards (Ind AS) via official exchange structured filings.
What should the next disclosure help confirm?
Monitor upcoming financial disclosures for sequential top-line and bottom-line trends.
07 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
08 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Subsequent Quarter Filings: Monitor upcoming financial disclosures for sequential top-line and bottom-line trends.
- 02
Subsequent Financial Disclosures: Monitor subsequent quarterly financial filings to evaluate sequential and year-over-year operational trends as comparable data becomes available.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.